Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed ...

Many considered it one of the most promising biotechs around. Celldex Therapeutics appeared to be on the cusp of a major breakthrough in brain cancer immunotherapy, with its market cap reflecting high ...

Celldex Therapeutics (CLDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of ...

We recently published a list of 8 Best Small-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands ...

What: Shares of the clinical-stage biotech Celldex Therapeutics are getting hammered Monday due to the failure of its late-stage brain cancer vaccine Rintega. Specifically, the drugmaker's shares ...

Shares of Celldex Therapeutics (CLDX) have gained 4% over the past four weeks to close the last trading session at $32.31, but there could still be a solid upside left in the stock if short-term price ...